This phase Ib trial evaluates a safe and effective dose of preoperative breast stereotactic body radiation therapy using the GammaPod machine to treat early stage breast cancer patients. Preoperative radiation therapy has been shown to reduce radiation treatment volumes (meaning the radiation covers a smaller portion of the body), improve cosmesis (skin changes), and shorten the course of radiation. For this trial, stereotactic body radiation therapy uses the GammaPod machine to position a patient and deliver radiation to tumors with high precision. A single dose of preoperative breast stereotactic body radiation therapy using the GammaPod machine may produce fewer side effects than standard treatment and improve cosmetic outcomes.
Additional locations may be listed on ClinicalTrials.gov for NCT04234386.
Locations matching your search criteria
United States
Maryland
Baltimore
University of Maryland/Greenebaum Cancer CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Bel Air
UM Upper Chesapeake Medical CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Columbia
Central Maryland Radiation Oncology in Howard CountyStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
Glen Burnie
UM Baltimore Washington Medical Center/Tate Cancer CenterStatus: Active
Contact: Elizabeth May Nichols
Phone: 410-328-6080
PRIMARY OBJECTIVE:
I. To establish the single-fraction radiation dose (MTD) delivered with the GammaPod that causes an incidence of dose-limiting toxicities (DLTs) that is statistically significantly 10% or lower.
SECONDARY OBJECTIVES:
I. To establish the comprehensive safety profile of single-fraction partial-breast irradiation (PBI) delivered with the GammaPod.
II. To establish the rate of pathologic complete response (pCR) as a function of dose.
OUTLINE: This is a dose-escalation study.
Patients undergo computed tomography and a single dose of breast stereotactic body radiation therapy (SBRT) using the GammaPod machine over 2 hours. Patients then undergo standard lumpectomy 4-12 weeks after breast SBRT.
After completion of study treatment, patients are followed up at 1, 6, and 12 months after surgery and then annually for 5 years.
Lead OrganizationUniversity of Maryland/Greenebaum Cancer Center
Principal InvestigatorElizabeth May Nichols